Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes Drug's hidden effects on body fuel production revealed

NCT ID NCT07053293

Recruiting now Knowledge-focused Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates how the diabetes medication empagliflozin influences the body's production of glucose, fats, and ketones in people with type 2 diabetes. Researchers will also test whether blocking the sympathetic nervous system with propranolol changes these effects. The goal is to understand the underlying mechanisms, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin (a diabetes drug) and propranolol (a beta-blocker)
What this could lead to
If successful, this could clarify how SGLT2 inhibitors work in the body, potentially leading to better diabetes management strategies.
What could go wrong
This is a small, early-phase mechanistic study, not designed to test treatment outcomes. Results may not translate to clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Diabetes Institute/UH

    RECRUITING

    San Antonio, Texas, 78229-3900, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.